Photo of Nicholas J. Landau, Ph.D.

Nick Landau advises clients in the procurement, protection and litigation of all forms of intellectual property, including patents, trademarks and trade secrets. He is particularly experienced in patent prosecution, having drafted over 150 patent applications in numerous areas of technology. His patent prosecution experience includes multiple successful ex parte appeals. He has worked with patents in a broad array of technological disciplines and has extensive knowledge in the areas of biotechnology, pharmaceuticals, nutraceuticals, medical devices and environmental technology. His clients include individuals, universities, startups, growing businesses and publicly traded companies. View articles by Nicholas

B.S. Environmental Science
Ph.D. Environmental Science with a Concentration in Environmental Microbiology

Patent Registration Number: 57,120

Eliminate Medical Treatment Patents? An Effort Approaches the Supreme CourtWill the Supreme Court’s banning of methods of medical diagnosis from patenting in Mayo v. Prometheus be extended to patents for medical treatments? Since Mayo some have argued that some methods of medical treatment should also be banned from patenting. Up until recently these arguments have seemed futile, as the U.S. Court of Appeals for

Patenting Diagnostics and Biomarkers Six Years After <i>Mayo</i>In 2012, the U.S. Supreme Court decided the landmark case of Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012), which was hailed by some as banning patents on methods of medical diagnosis. It appeared to be the end of the road for the development of personalized medicine for profit, at least

Rules for Patenting Genetic Biomarkers Are Updated in Roche v. CepeidAs the readers of this blog are no doubt aware, patenting DNA defined only by a naturally occurring nucleotide sequence was banned by the U.S. Supreme Court in the landmark case of Association for Molecular Pathology v. Myriad Genetics, Inc. The patentee in that case attempted to patent “isolated” DNA with the natural sequence